Search

The wide application of direct ethanol fuel cells (DEFCs) was blocked by the sluggish catalytic activity of catalysts, insufficient ionic conductivity of the polymer electrolyte membrane (PEM), and ethanol crossover issues. To overcome the problems mentioned above, a novel DEFC system with a polymer fiber membrane (PFM) and nonplatinum catalysts is proposed. In this system, the performance of the anode catalyst Pd/C is significantly promoted by homogeneous Ni-doped SnO2nanoparticles, and the inexpensive permeable PFM is used as a substitute for the PEM. Due to the remarkable catalytic activity and the optimized resistance, the PFM-based DEFC exhibits encouraging performance, which can afford a peak power density of 47.4 mW cm−2with a porous NiCo2O4cathode catalyst. Moreover, it can operate continuously for 100 h with only 4.56% drop in electrical output. Therefore, this study provides a very effective strategy for optimizing DEFCs with low cost and high performance.

To reveal the dynamic mechanical characteristics of deep rocks, a series of impact tests under triaxial static stress states corresponding to depths of 300–2400 m were conducted. The results showed that both the strain rates and the stress environments in depth significantly affect the mechanical characteristics of rocks. The sensitivity of strain rate to the dynamic strength and deformation modulus shows a negative correlation with depth, indicating that producing penetrative cracks in deep environments is more difficult when damage occurs. The dynamic strength shows a tendency to decrease and then increase slightly, but decreases sharply finally. Transmissivity demonstrates a similar trend as that of strength, whereas reflectivity indicates the opposite trend. Furthermore, two critical depths with high dynamically induced hazard possibilities based on the China Jinping Underground Laboratory (CJPL) were proposed for deep engineering. The first critical depth is 600–900 m, beyond which the sensitivity of rock dynamic characteristics to the strain rate and restraint of circumferential stress decrease, causing instability of surrounding rocks under axial stress condition. The second one lies at 1500–1800 m, where the wave impedance and dynamic strength of deep surrounding rocks drop sharply, and the dissipation energy presents a negative value. It suggests that the dynamic instability of deep surrounding rocks can be divided into dynamic load dominant and dynamic load induced types, depending on the second critical depth.

Purpose: The purpose of this study is to assess the efficacy and safety of cilostazol prescription in patients with femoropopliteal peripheral artery disease (PAD) after endovascular therapy (EVT).Materials and methods: We conducted a systematic review and meta-analysis of all studies reporting the outcomes of cilostazol after femoropopliteal EVT of PAD up to September 2022. Clinical outcomes of interest included primary patency, in-stent restenosis (ISR), vessel re-occlusion, freedom from target lesion revascularization (TLR), repeat revascularization, all-cause mortality, amputation, major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs), and bleeding complication.Results: A total of 4 randomized controlled trials (RCTs) and 8 observational studies containing a total of 4898 patients met the inclusion criteria and were included in this systematic review and meta-analysis. We found that the use of cilostazol was associated with higher primary patency after femoropopliteal artery EVT (odds ratio [OR]=1.67, 95% confidence interval [CI]=1.50-1.87, p<0.001, I2=33.2%), a lower risk of ISR (OR=0.43, 95% CI=0.29-0.63, p<0.001, I2=37.6%), repeat revascularization (OR=0.43, 95% CI=0.24-0.76, p<0.005, I2=27.4%), and vessel re-occlusion (OR=0.59, 95% CI=0.38-0.93, p<0.05, I2=0%). There was an increase in freedom from TLR rate (OR=2.19, 95% CI=1.58-3.05, p<0.001, I2=0%), as well as a reduction in the occurrence of MALEs (OR=0.50, 95% CI=0.29-0.85, p<0.05, I2=0%). However, there was no significant difference in amputation, MACEs, all-cause mortality, and major bleeding complications. Subgroup analysis showed that cilostazol treatment in patients with femoropopliteal drug-eluting stents (DES) implantation remained associated with higher primary patency and a lower risk of ISR.Conclusions: After EVT of femoropopliteal artery lesions, additional oral cilostazol enhances primary patency, reduces the occurrences of ISR and vessel re-occlusion, diminishes the risks associated with MALEs, lowers the need for repeat revascularization, and increases freedom from TLR rates. However, it does not impact amputation, MACEs, all-cause mortality, or major bleeding complications. These findings suggest cilostazol as a potentially safe and effective adjunct therapy in patients with femoropopliteal PAD after EVT.Clinical Impact After undergoing endovascular therapy (EVT) for femoropopliteal artery lesions, the addition of cilostazol to antiplatelet therapy can significantly improve primary patency, reducing the incidence of in-stent restenosis, repeat revascularization, vessel re-occlusion, and major adverse limb events while increasing freedom from target lesion revascularization rate. The simultaneous use of drug-eluting stents in the femoropopliteal artery lesions, combined with cilostazol, potentially results in a synergistic anti-stenotic effect. This therapeutic approach does not appear to be associated with an increased risk of major bleeding events or all-cause mortality. These findings provide additional evidence supporting the treatment of anti-stenosis in patients with femoropopliteal artery lesions after EVT.

Vapor-solid reaction methods are highly regarded as potential solutions for large-scale production of perovskite thin films due to their scalability, compatibility with silicon tandem technology, and lack of solvents. However, the limited penetration of organic vapor through the solid inorganic film results in a slow growth rate of perovskite, leading to poor crystallinity and small grain size. This high defect density in the grain boundaries hinders the enhancement of device performance. In this study, we used 1,3-diaminoguanidine monohydrochloride as an additive in the PbI2precursor films, which effectively improved perovskite grain growth in the vapor-solid reaction process. After optimization, we achieved high-quality perovskite thin films with a large grain size exceeding 5 μm. Notably, solar devices based on these large grain perovskite thin films achieved a high power conversion efficiency up to 21.13%.

The metal–nitrogen–carbon (M–N–C)-based catalysts are promising to replace PGM (platinum group metal) to accelerate oxygen reduction reaction due to their excellent electrocatalytic performance. However, the inferior intrinsic activity and poor active site density confining further improvement in their performance. Modulating the electronic structure and reasonably designing the pore structure are widely acknowledged effective strategies to boost the activity of the M–N–C catalysts. However, it is a great challenge to form abundant pores to regulate the electronic structure via the facile method. Herein, a hierarchical, porous dual-atom catalyst FeNi-NPC-1000 has been architectured by the Na2CO3template method and bimetallic doping modification strategy. Benefitting from the optimized pore and electronic structure, the as-prepared FeNi-NPC-1000 possesses a high specific surface area (1412.8 m2g–1) and improved ORR activity (E1/2= 0.877 V vs RHE), which is superior to that of Pt/C (E1/2= 0.867 V vs RHE). With the evidence of AC-STEM, XAS, and DFT, the FeNi-N8-C moiety is proven to be the key active site to realize high-efficiency ORR catalysis. When assembled it as an air cathode of ZABs, FeNi-NPC-1000 displays superior discharge performance (Pmax= 367.1 mW cm–2) and a stable battery long-life. This article will provide a new strategy for designing dual-metal atomic catalysts applied in metal–air batteries.

Hepatocellular carcinoma (HCC) is a typical hypervascular solid tumor. Vasculogenic mimicry (VM) formed by aggressive tumor cells to mimic vasculogenic networks plays an important role in the tumor malignancy of HCC. Hsp90β promotes endothelial cell-dependent angiogenesis in HCC. However, the relationship between Hsp90β and VM formation is unclear. In this study, we found that Hsp90β is positively correlated with VM and EMT marker proteins in HCC tissues and promotes tube formation, cell migration, and invasion in vitro. Hsp90β interacts with Twist1 and promotes its deubiquitination and stabilization to nuclear translocation and enhances the VE-cadherin promoter activity. Results of in vitro analysis indicate that Hsp90β enhances the tumor VM in tumor-burdened mice, and the Hsp90 inhibitor NVP-BEP800 suppresses VM formation by releasing Hsp90β and Twist1 interaction. This study provides a potential antitumor therapy for inhibiting VM by targeting Hsp90β in HCC.